Hypertensive crisis after using zuclopenthixol decanoate: importance of starting oral formulations before starting depot antipsychotics

---

Atıf İçin Kopyala

Han Almis B., Tasolar M. H., Celik M.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, cilt.18, ss.62-64, 2017 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 18
• Basım Tarihi: 2017
• Doi Numarası: 10.5455/apd.250929
• Dergi Adı: ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.62-64
• İnönü Üniversitesi Adresli: Hayır

Özet

Zuclopenthixol decanoate depot is an effective and safe antipsychotic which is treatment choice particularly in noncompliant patients with schizophrenia. In this article, a case developing hypertensive crisis after zuclopenthixol decanoate depot is reported first time in the literature. As in other antipsychotics, risk of life threatening adverse effects does exist also after zuclopenthixol decanoate injection and since elimination of depot antipsychotics from the body may take weeks or months, clinicians should be aware of risk imposed by starting therapy directly by a depot antipsychotic.